Vaxart Announces Adjournment of Annual Meeting of Stockholders
SOUTH SAN FRANCISCO, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) ('Vaxart' or the 'Company') announced today that its 2025 annual meeting of stockholders (the 'Annual Meeting') has been adjourned to Monday, June 2, 2025 at 8:30 a.m. Pacific Time with respect to all proposals described in Vaxart's definitive proxy statement filed with the U.S. Securities and Exchange Commission (the 'SEC') on April 10, 2025 (the 'Proxy Statement').
The reconvened Annual Meeting will be held in a virtual-only format, which can be accessed by visiting http://www.virtualshareholdermeeting.com/VXRT2025 and entering the 16‐digit control number included in your Notice of Internet Availability of Proxy Materials, on your proxy card or in the instructions that accompanied your proxy materials.During the adjournment, Vaxart continues to solicit votes from its stockholders with respect to all proposals set forth in the Proxy Statement.
Proxies previously submitted with respect to the Annual Meeting will be voted on all applicable proposals at the adjourned Annual Meeting unless properly revoked in accordance with the procedures described in the Proxy Statement, and stockholders who have previously submitted a proxy or otherwise voted need not take any action.
The Board of Directors of Vaxart believes that the approval of Proposal No. 2 regarding the Reverse Stock Split is in the best interests of the stockholders of Vaxart for the following reasons:
regains compliance of Nasdaq's minimum bid price requirement and helps ensure that the Company's common stock can remain listed on Nasdaq;
brokerage firms may be more reluctant to recommend lower priced securities to their clients and investors may also be dissuaded from purchasing lower priced stocks because the brokerage commissions, as a percentage of the total transaction, tend to be higher for such stocks;
analysts at many brokerage firms do not monitor the trading activity or otherwise provide coverage of lower priced stocks and that most investment funds are reluctant to invest in lower priced stocks; and
a higher stock price may help generate investor interest in the Company and help the Company attract and retain employees.
Vaxart encourages all stockholders of record on March 26, 2025 who have not yet voted to do so by 11:59 p.m. Eastern Time on June 1, 2025. The Company also reminds those who have previously voted against Proposal No. 2 that they can change their vote in favor of the proposal.
If you have any questions or need assistance with voting, please contact Vaxart's proxy solicitation firm:
Campaign Management, LLCToll-Free: 1-855-264-1527Email: info@campaign-mgmt.com
About Vaxart Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart's development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the 'Securities Act') and Section 21E of the Securities Exchange Act of 1934, as amended (the 'Exchange Act'), which are subject to the 'safe harbor' created by those sections, concerning our business, operations, and financial performance and condition as well as the annual meeting of stockholders, our plans, objectives, and expectations for business operations, funding, and financial performance and condition. Any statements contained herein that are not of historical facts may be deemed to be forward-looking statements. You can identify these statements by words such as 'anticipate,' 'assume,' 'believe,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'should,' 'will,' 'would,' and other similar expressions that are predictions of or indicate future events and future trends. These forward-looking statements are based on current expectations, estimates, forecasts, and projections about our business and the industry in which we operate and management's beliefs and assumptions and are not guarantees of future performance or development and involve known and unknown risks, uncertainties, and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this press release may turn out to be inaccurate. Factors that could materially affect our business operations and financial performance and condition include, but are not limited to, those risks and uncertainties described under 'Item 1A - Risk Factors' in our Annual Report on Form 10-K for the year ended December 31, 2024 and any risk factors disclosed in any subsequent Quarterly Reports on Form 10-Q. You are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are based on information available to us as of the date of this press release. Unless required by law, we do not intend to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise. You should, however, review the factors and risks we describe in the reports we will file from time to time with the SEC after the date of this press release.
Participants in the SolicitationThe Company and its directors, executive officers, and certain employees and other persons may be deemed to be participants in the solicitation of proxies from the Company's stockholders in connection with the business to be conducted at the annual meeting of stockholders. Investors and security holders may obtain more detailed information regarding the names, affiliations, and interests of the Company's directors and executive officers in the definitive proxy statement filed in connection with the annual meeting of stockholders as well as the Company's other filings with the U.S. Securities and Exchange Commission (the 'SEC'), all of which may be obtained free of charge at the website maintained by the SEC at www.sec.gov.
Contact
Vaxart Media and Investor Relations Matt SteinbergFINN PartnersIR@vaxart.com(646) 871-8481
This press release was published by a CLEAR® Verified individual.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
26 minutes ago
- Associated Press
Torq Completes $3.12 Million Recapitalization Transactions
NOT FOR DISTRIBUTION TO U.S. WIRE SERVICES OR FOR DISTRIBUTION INTO THE UNITED STATES VANCOUVER, BC / ACCESS Newswire / June 6, 2025 / Torq Resources Inc. (TSXV:TORQ)(OTCQB:TRBMF) ('Torq' or the 'Company') is pleased to announce that, further to its March 24, 2025 news release, it has completed its previously announced private placement, by issuing 25,152,633 units of the Company (each, a 'Unit') at an offering price of $0.06 per Unit for gross proceeds of C$1,509,158 (the 'Offering'). Each Unit consists of one common share (a 'Share') and a Share purchase warrant (each, a 'Warrant') exercisable until June 6, 2027 to acquire a Share for C$0.12. The Warrants are subject to an accelerated expiry if, anytime following the date that is four months after the Closing Date, the closing price of the common shares of the Company on the TSXV, or such other market as the common shares may trade from time to time, is or exceeds $0.30 for any 10 consecutive trading days, in which event the holder of the Warrants may, at the Company's election, be given notice and the Company will issue a press release announcing that the financing Warrants will expire 30 days following the date of such press release. The Offering Warrants may be exercised by the holder of the Warrant during the 30-day period after the date of the press release announcing the accelerated expiry date. The placement proceeds from the Offering will be used for working capital. In addition, the Company has issued 1,998,829 Shares to non-arm's length creditors and 19,619,394 Units (identical to those in the Offering) to arm's length creditors to settle an aggregate of $1,297,093.60 of debts (the 'Debt Settlement'). The debts relate primarily to the 2024 Minera Santa Drilling Campaign and also include $310,000 which was advanced and spent pursuant to the previous private placement financing, announced on October 2, 2024 and November 18, 2024, which did not complete. In connection with the closing of the Offering, the Company paid cash finder's fees of $51,012 and issued 800,200 non-transferable one-year finder's warrants. Each finder's warrant will entitle the holder thereof to purchase one common share of the Company at the exercise price of C$0.06 until June 6, 2026. Each finder's warrant is also subject to the accelerated expiry as described above. The Company is continuing to seek regulatory approval for the extension of its credit facility for a further one-year period until July 11, 2026. In accordance with applicable securities laws, the securities issued under the Offering and Debt Settlement are subject to a statutory four-month and one-day hold period from the date of issuance in Canada. There was no insider participation in the Offering. 1,998,829 shares were issued to non-arm's length creditors in the Debt Settlement. The Company will be relying on the exemption from the formal valuation and minority shareholder approval requirements pursuant to sections 5.5(a) and 5.7(1)(a) of Canadian Multilateral Instrument 61-101 - Protection of Minority Shareholders in Related Party Transactions, as neither the fair market value of any securities issued to nor the consideration paid by such person could exceed $2.5 million or 25% of the Company's market capitalization. None of these securities will be registered under the United States Securities Act of 1933, as amended (the 'U.S. Securities Act'), or any U.S. state securities laws, and may not be offered or sold in the United States without registration under the U.S. Securities Act and all applicable state securities laws or else in compliance with the requirements of an applicable exemption therefrom. A Message from Shawn Wallace, CEO: 'The Offering and Debt Settlement transactions greatly improve our financial position and should provide the impetus for a more active 2025. We are looking forward to the receipt of assays on the Santa Cecilia project where exploration funding is being provided by Gold Fields under an earn-in option.' ON BEHALF OF THE BOARD, Shawn Wallace CEO & Chair For further information on Torq Resources, please visit or contact the company at (778) 729-0500 or [email protected]. About Torq Resources Torq is a Vancouver-based copper and gold exploration company with a portfolio of premium holdings in Chile. The Company is establishing itself as a leader of new exploration in prominent mining belts, guided by responsible, respectful and sustainable practices. The Company was built by a management team with prior success in monetizing exploration assets and its specialized technical team is recognized for their extensive experience working with major mining companies, supported by robust safety standards and technical proficiency. The technical team includes Chile-based geologists with invaluable local expertise and a noteworthy track record for major discovery in the country. Torq is committed to operating at the highest standards of applicable environmental, social and governance practices in the pursuit of a landmark discovery. For more information, visit Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. SOURCE: Torq Resources Inc. press release
Yahoo
26 minutes ago
- Yahoo
India Wind Turbine Industry Report 2025: $4.84 Bn Market Trends, Competitive Landscape, Forecasts & Opportunities 2021-2031 - Growing Government Policies, Rise of Wind-Solar Hybrid Projects
Key market opportunities in India's wind turbine sector include robust government support with favorable policies, the rise of wind-solar hybrid projects enhancing efficiency, and technological advancements boosting reliability. Despite challenges like land acquisition issues, the drive for renewable energy presents substantial growth potential. Indian Wind Turbine Market Dublin, June 06, 2025 (GLOBE NEWSWIRE) -- The "India Wind Turbine Market, By Region, Competition, Forecast & Opportunities, 2021-2031F" report has been added to India Wind Turbine Market was valued at USD 3.18 Billion in 2025, and is expected to reach USD 4.84 Billion by 2031, rising at a CAGR of 7.10% Wind turbines, which transform wind's kinetic energy into electricity through rotor-driven generators, are pivotal to the country's clean energy strategy. Predominantly installed in high-wind regions such as coastal and open plains, they are available in horizontal-axis and vertical-axis configurations, with the former being more widespread. As environmentally friendly power sources, wind turbines produce no direct emissions and are integrated with advanced systems to ensure optimized and safe operations. Despite challenges like intermittency and noise, wind energy offers vital benefits in emission reduction and energy security. Advancements in turbine technology continue to enhance efficiency and reliability, reinforcing wind power's essential role in India's transition to sustainable energy. Key Market Drivers Government Policies and IncentivesA major driver of India's wind turbine market is the robust government support manifested through favorable policies, financial subsidies, and regulatory initiatives. The Ministry of New and Renewable Energy (MNRE) has laid out ambitious plans to reach 140 GW of wind capacity by 2030. To facilitate this goal, the government has introduced measures like Accelerated Depreciation (AD), Generation-Based Incentives (GBI), and concessional financing to reduce project costs and attract private and foreign investments. Competitive bidding for wind energy projects fosters cost efficiency and transparency. Additionally, the rollout of wind-solar hybrid policies and offshore wind guidelines has broadened the market potential, supporting the development of integrated renewable infrastructure across the Market Challenges Land Acquisition and Infrastructure BottlenecksA significant hurdle for the Indian wind turbine sector is the complex and time-consuming process of land acquisition and the insufficient infrastructure in high-potential areas. Although states such as Tamil Nadu, Gujarat, and Maharashtra offer strong wind resources, securing land for projects often involves dealing with bureaucratic delays, unclear land titles, and local resistance. Communities may oppose projects due to fears of displacement, disruption to traditional land use, and perceived inadequate compensation. Furthermore, many optimal wind sites are in remote locations that lack critical infrastructure like roads and power evacuation systems. In several cases, completed wind farms are underutilized due to inadequate transmission connectivity, causing financial setbacks for Market Trends Rise of Wind-Solar Hybrid ProjectsAn emerging trend in India's wind energy landscape is the rise of wind-solar hybrid projects, which combine both energy sources at a shared site or grid point. This setup enhances land and infrastructure use efficiency and delivers a more stable power supply. Recognizing the value of hybrid models, the government launched the National Wind-Solar Hybrid Policy, aimed at improving grid reliability and optimizing energy output. These projects allow for shared infrastructure, resulting in cost savings and operational efficiency. Technological innovations are also supporting this trend, with customized solutions such as hybrid-compatible inverters and control systems. States like Gujarat and Rajasthan, with rich wind and solar potential, are leading hybrid deployments, and key industry players are actively participating in hybrid tenders, signifying growing market traction. Key Attributes: Report Attribute Details No. of Pages 86 Forecast Period 2025 - 2031 Estimated Market Value (USD) in 2025 $3.18 Billion Forecasted Market Value (USD) by 2031 $4.84 Billion Compound Annual Growth Rate 7.1% Regions Covered India Report Scope: Competitive LandscapeCompany Profiles: Detailed analysis of the major companies present in the India Wind Turbine Market. Vestas Wind Systems A/S Siemens Gamesa Renewable Energy, S.A. General Electric Company (GE Renewable Energy) Nordex SE Goldwind Science & Technology Co., Ltd. Envision Energy Suzlon Energy Limited Mingyang Smart Energy Group Co., Ltd. India Wind Turbine Market, By Type: Horizontal-Axis Turbine Vertical-Axis Turbine India Wind Turbine Market, By Installation: Offshore Onshore India Wind Turbine Market, By Component: Foundation Tower Rotor Generator Nacelle Others India Wind Turbine Market, By Application: Industrial Commercial Residential Utilities India Wind Turbine Market, By Rating: < 100KW 100KW to 250KW 250KW to 500KW 500KW to 1MW 1MW to 2MW >2MW India Wind Turbine Market, By Region: South India North India West India East India For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Indian Wind Turbine Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Associated Press
27 minutes ago
- Associated Press
Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer
– This submission is supported by the pivotal Phase 3 VERITAC-2 clinical trial, results of which were recently presented at the 2025 American Society for Clinical Oncology Annual Meeting and published in The New England Journal of Medicine – – VERITAC-2 data support vepdegestrant as a potential treatment option in patients with ESR1m ER+/HER2- advanced or metastatic breast cancer – NEW HAVEN, Conn., June 06, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) with its partner Pfizer Inc. (NYSE: PFE), for vepdegestrant for the treatment of patients with ER-positive (ER+)/human epidermal growth factor receptor 2 (HER2)-negative (ER+/HER2-) ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. This submission is based on results from VERITAC-2 (NCT05654623), a global, randomized Phase 3 trial evaluating vepdegestrant versus fulvestrant. 'This milestone comes after an exciting presentation at the American Society of Clinical Oncology's annual meeting,' said John Houston, Ph.D., Chairperson, Chief Executive Officer and President at Arvinas. 'We look forward to the NDA review and to the first ever FDA-approved PROTAC ER degrader potentially being available to patients who could benefit from a much needed, new treatment option.' Vepdegestrant is being jointly developed by Arvinas and Pfizer for the treatment of patients with advanced or metastatic ER+/HER2- breast cancer and was granted fast track designation as a monotherapy by the FDA. Results from the VERITAC-2 study were recently presented in a late-breaking oral presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting and were selected for the ASCO press briefing and for Best of ASCO. Detailed results were also simultaneously published in the New England Journal of Medicine. About the VERITAC-2 Clinical Trial The Phase 3 VERITAC-2 clinical trial ( NCT05654623 ) is a global, randomized trial evaluating the efficacy and safety of vepdegestrant (ARV-471) as a monotherapy compared to fulvestrant in patients with ER+/HER2- advanced or metastatic breast cancer. The trial enrolled 624 patients at sites in 25 countries who had previously received treatment with a CDK4/6 inhibitor plus endocrine therapy. Patients were randomized 1:1 to receive either vepdegestrant once daily, orally on a 28-day continuous dosing schedule, or fulvestrant, administered intramuscularly on Days 1 and 15 of Cycle 1 and then on Day 1 of each 28-day cycle starting from Day 1 of Cycle 2. In the trial, 43% of patients (n=270) had ESR1 mutations detected. The primary endpoint was progression-free survival (PFS) in the ESR1-mutation and intent-to-treat populations as determined by blinded independent central review. Overall survival is the key secondary endpoint. About Vepdegestrant Vepdegestrant is an investigational, orally bioavailable PROTAC (PROteolysis TArgeting Chimera) protein degrader designed to specifically target and degrade the estrogen receptor (ER). Vepdegestrant is being developed as a potential monotherapy for ER+/HER2- advanced or metastatic breast cancer with estrogen receptor 1 (ESR1) mutations in the second line-plus setting. In July 2021, Arvinas announced a global collaboration with Pfizer for the co-development and co-commercialization of vepdegestrant; Arvinas and Pfizer will share worldwide development costs, commercialization expenses, and profits. The U.S. Food and Drug Administration (FDA) has granted vepdegestrant Fast Track designation as a monotherapy in the treatment of adults with ER+/HER2- advanced or metastatic breast cancer previously treated with endocrine-based therapy. About Arvinas Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body's natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and ARV-102, targeting LRRK2 for neurodegenerative disorders. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit and connect on LinkedIn and X. Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding: the NDA review and to the first ever FDA-approved PROTAC ER degrader potentially being available to patients who could benefit from a much needed, new treatment option; and vepdegestrant's development as a potential monotherapy for ER+/HER2- advanced or metastatic breast cancer with ESR1 mutations in the second line-plus setting. All statements, other than statements of historical fact, contained in this press release, including statements regarding Arvinas' strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words 'anticipate,' 'believe,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'target,' 'goal,' 'potential,' 'will,' 'would,' 'could,' 'should,' 'look forward,' 'continue,' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Arvinas may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Arvinas makes as a result of various risks and uncertainties, including but not limited to: whether Arvinas and Pfizer will successfully perform their respective obligations under the collaboration between Arvinas and Pfizer; whether Arvinas and Pfizer will be able to successfully conduct and complete clinical development for vepdegestrant as a monotherapy; whether the VERITAC-2 clinical trial will meet the secondary endpoint for overall survival; risks related to our expectations regarding the potential clinical benefit of vepdegestrant to patients; uncertainties relating to regulatory applications and related filing and approval timelines, including the New Drug Application seeking FDA approval of vepdegestrant and the risk that any regulatory approvals, if granted, may be subject to significant limitations on use or subject to withdrawal or other adverse actions by the applicable regulatory authority; whether FDA or other regulatory authorities will require additional information or further studies, or may fail or refuse to approve or may delay approval of vepdegestrant; whether Arvinas and Pfizer, as appropriate, will be able to obtain marketing approval for and commercialize vepdegestrant and other product candidates on current timelines or at all; Arvinas' ability to protect its intellectual property portfolio; Arvinas' reliance on third parties; whether Arvinas will be able to raise capital when needed; whether Arvinas' cash and cash equivalent resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; and other important factors discussed in the 'Risk Factors' section of Arvinas' Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent other reports on file with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release reflect Arvinas' current views with respect to future events, and Arvinas assumes no obligation to update any forward-looking statements, except as required by applicable law. These forward-looking statements should not be relied upon as representing Arvinas' views as of any date subsequent to the date of this release. Contacts Investors: Jeff Boyle +1 (347) 247-5089 [email protected] Media: Kirsten Owens +1 (203) 584-0307 [email protected]
